Insights

Innovative Pain Therapy MAXONA Pharmaceuticals is developing a novel, non-opioid, non-NSAID pain management therapy, MAX-001, which addresses a significant market need for safer pain treatments without the risks of addiction or side effects, presenting a unique sales opportunity within pain management drug markets.

Clinical Stage Focus As a clinical-stage company leveraging cutting-edge research, MAXONA is open to partnerships and collaborations with pharmaceutical firms, research institutions, and healthcare providers seeking innovative therapies, opening avenues for co-development and licensing deals.

Growing Market Potential With a revenue ranging between 1M and 10M and a focus on a large unmet medical need, MAXONA's growth trajectory offers potential for future expansion into chronic and acute pain treatment markets, appealing to investors and regional partners.

Leadership and Expertise The company boasts an experienced leadership team with proven success in pharmaceutical development and commercialization, making it a reliable partner for healthcare organizations looking to expand their pain management portfolios.

Technology and Data Focus MAXONA's utilization of advanced tech tools indicates a data-driven approach and modern development strategies that can be leveraged to streamline collaboration efforts, improve outreach, and enhance stakeholder engagement in drug development and commercialization.

MAXONA Pharmaceuticals Tech Stack

MAXONA Pharmaceuticals uses 8 technology products and services including Open Graph, RSS, Webpack, and more. Explore MAXONA Pharmaceuticals's tech stack below.

  • Open Graph
    Content Management System
  • RSS
    Content Management System
  • Webpack
    Development
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • HSTS
    Security
  • X-Content-Type-Options
    Web & Portal Technology
  • Google Analytics
    Web Analytics

Media & News

MAXONA Pharmaceuticals's Email Address Formats

MAXONA Pharmaceuticals uses at least 1 format(s):
MAXONA Pharmaceuticals Email FormatsExamplePercentage
FLast@maxonapharm.comJDoe@maxonapharm.com
100%

Frequently Asked Questions

Where is MAXONA Pharmaceuticals's headquarters located?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals's main headquarters is located at 101 Lindenwood Drive Suite 225 Malvern, Pennsylvania 19355 United States. The company has employees across 2 continents, including North AmericaAsia.

What is MAXONA Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals's official website is maxonapharm.com and has social profiles on LinkedInCrunchbase.

What is MAXONA Pharmaceuticals's NAICS code?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does MAXONA Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of April 2026, MAXONA Pharmaceuticals has approximately 9 employees across 2 continents, including North AmericaAsia. Key team members include President & Ceo: S. F.Consultant: R. B.Board Member: D. N.. Explore MAXONA Pharmaceuticals's employee directory with LeadIQ.

What industry does MAXONA Pharmaceuticals belong to?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does MAXONA Pharmaceuticals use?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals's tech stack includes Open GraphRSSWebpackFont AwesomejQueryHSTSX-Content-Type-OptionsGoogle Analytics.

What is MAXONA Pharmaceuticals's email format?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals's email format typically follows the pattern of FLast@maxonapharm.com. Find more MAXONA Pharmaceuticals email formats with LeadIQ.

When was MAXONA Pharmaceuticals founded?

Minus sign iconPlus sign icon
MAXONA Pharmaceuticals was founded in 2016.

MAXONA Pharmaceuticals

Pharmaceutical ManufacturingPennsylvania, United States2-10 Employees

MAXONA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company leveraging innovation to develop the next generation of therapies to help patients maximize life. 

MAXONA's  initial focus is on addressing the urgent need for new effective therapies that treat acute and chronic pain, without the side effects and addiction risks associated with NSAIDS and opioids.

MAXONA's lead compound, MAX-001 is a non-opioid, non-NSAID oral therapy 
with a novel mechanism of action that is initially being developed in the U.S. to treat acute and chronic pain. MAX-001 is a patent protected optimized formulation of nefopam. which is widely used and extensively studied outside the U.S. to treat acute and chronic pain.

MAXONA has assembled a highly experienced and well recognized leadership team with a proven record of successfully developing and commercializing effective therapeutics. With deep experience in all areas of clinical development and commercialization, the leadership team is well-equipped to realize MAXONA's vision to help patients maximize life.

Section iconCompany Overview

Headquarters
101 Lindenwood Drive Suite 225 Malvern, Pennsylvania 19355 United States
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2016
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $1M$10M

    MAXONA Pharmaceuticals's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    MAXONA Pharmaceuticals's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

ยฉ LeadIQ, Inc. All rights reserved.